Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Cancer - Lung
John McCann, MD
D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
For this sub-study, you will be assigned to treatment with talazoparib (BMN 673), a PARP inhibitor. The purpose of this sub-study is to find any good and bad effects of talazoparib (BMN 673). Talazoparib (BMN 673) may or may not shrink your cancer and it could also cause side effects.
Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer